Academic Rheumatology Department, Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.
MRC Integrative Epidemiology Unit, Bristol Medical School (PHS), University of Bristol, Bristol, UK.
Rheumatology (Oxford). 2020 Oct 1;59(10):2898-2907. doi: 10.1093/rheumatology/keaa044.
Statins are reported to have a potential benefit on progression of OA and on disease activity in RA, but existing evidence is conflicting. Our objective was to examine whether statins associate with reduction in the risk for joint replacement due to OA and RA.
This was a propensity score-matched cohort study. Electronic health records from the UK Clinical Practice Research Datalink were used. We selected people prescribed statins and people never prescribed statins. Each statin user was matched to a non-user by age, gender, practice and propensity score for statin prescription. The main outcome measures were knee or hip joint replacement overall, and specifically because of OA or RA. The association between statins and risk of joint replacement was assessed using Cox proportional hazard regression. Statin exposure was categorized according to the potency of reducing low-density lipoprotein as low (21-28%), medium (32-38%) or high (42-55%) intensity.
A total of 178 467 statin users were matched with 178 467 non-users by age, gender, practice and propensity score. Overall, statin was not associated with reduced risk of knee or hip replacement (hazard ratio 0.99, 95% CI: 0.97, 1.03), unless prescribed at high strength (0.86, 0.75-0.98). The reduced risk was only observed for joint replacement due to RA (0.77, 0.63-0.94) but not OA (0.97, 0.94-1.01).
Statins at high intensity may reduce the risk of hip or knee replacement. This effect may be RA specific. Further studies to investigate mechanisms of risk reduction and the impact in people with RA are warranted.
据报道,他汀类药物对骨关节炎(OA)的进展和类风湿关节炎(RA)的疾病活动具有潜在益处,但现有证据存在冲突。我们的目的是研究他汀类药物是否与 OA 和 RA 导致的关节置换风险降低相关。
这是一项倾向评分匹配的队列研究。使用了英国临床实践研究数据链接的电子健康记录。我们选择了开处方他汀类药物的人和从未开处方他汀类药物的人。每个他汀类药物使用者都通过年龄、性别、实践和他汀类药物处方的倾向评分与非使用者匹配。主要观察指标是膝关节或髋关节置换的总体情况,以及由于 OA 或 RA 导致的置换情况。使用 Cox 比例风险回归评估他汀类药物与关节置换风险之间的关联。根据降低低密度脂蛋白的效力,他汀类药物暴露分为低(21-28%)、中(32-38%)或高(42-55%)强度。
共有 178467 名他汀类药物使用者与年龄、性别、实践和倾向评分匹配的 178467 名非使用者相匹配。总体而言,他汀类药物与膝关节或髋关节置换风险降低无关(风险比 0.99,95%CI:0.97,1.03),除非以高强度处方(0.86,0.75-0.98)。这种风险降低仅在 RA 导致的关节置换中观察到(0.77,0.63-0.94),而不是 OA(0.97,0.94-1.01)。
高强度的他汀类药物可能会降低髋关节或膝关节置换的风险。这种效果可能是 RA 特异性的。需要进一步研究以探讨风险降低的机制及其对 RA 患者的影响。